Key result
Pharmacologic therapies targeting neurohormonal activation, such as ACE inhibitors and beta-blockers, hold promise for altering the course of heart failure despite high residual mortality.
A narrative review summarizing the pathophysiologic rationale and clinical role of neurohormonal antagonists in the pharmacologic management of heart failure.
No takes yet. Share an insight, caveat, or question.
May support neurohormonal blockade in HF care; leaves open strategies to further reduce residual mortality.
Michael et al. (1998) conducted a review in Heart failure. Pharmacologic therapy (ACE inhibitors, beta-blockers, digoxin, etc.) was evaluated. Pharmacologic therapies targeting neurohormonal activation, such as ACE inhibitors and beta-blockers, hold promise for altering the course of heart failure despite high residual mortality.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: